IFN-α) nasal drops as a prophylactic measure [22]. Furthermore, a recent retrospective study in treated Chinese patients revealed that Tα1 significantly reduced the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells [23].
However, there are two major drawbacks of the currently marketed Tα1, both of which are related to its peptidic nature. First, the biopharmaceutical production of Tα1 is challenging. Ap